Respiratory Bacteria Vaccines: Model Analyses for Vaccine and Vaccine Trial Design Jim Koopman MD MPH Ximin Lin MD MPH Tom Riggs MD MPH Dept. of Epidemiology.

Slides:



Advertisements
Similar presentations
15 The Genetic Basis of Complex Inheritance
Advertisements

Agency for Healthcare Research and Quality (AHRQ)
Disease emergence in immunocompromised populations Jamie Lloyd-Smith Penn State University.
SEM PURPOSE Model phenomena from observed or theoretical stances
Sample size estimation
CHAPTER 21 Inferential Statistical Analysis. Understanding probability The idea of probability is central to inferential statistics. It means the chance.
Estimating the Effects of Treatment on Outcomes with Confidence Sebastian Galiani Washington University in St. Louis.
A VERY IMPORTANT CONCEPT Disease epidemiology is first and foremost a population biology problem Important proponents: Anderson, May, Ewald, Day, Grenfell.
Portfolio Diversity and Robustness. TOC  Markowitz Model  Diversification  Robustness Random returns Random covariance  Extensions  Conclusion.
In biology – Dynamics of Malaria Spread Background –Malaria is a tropical infections disease which menaces more people in the world than any other disease.
Dengue Transfusion Risk Model Lyle R. Petersen, MD, MPH Brad Biggerstaff, PhD Division of Vector-Borne Diseases Centers for Disease Control and Prevention.
The current status of fisheries stock assessment Mark Maunder Inter-American Tropical Tuna Commission (IATTC) Center for the Advancement of Population.
Population dynamics of infectious diseases Arjan Stegeman.
Clustered or Multilevel Data
Vaccination Externalities Bryan L. Boulier Tejwant S. Datta† Robert S. Goldfarb‡ The George Washington University, †Albert Einstein Medical.
The role of cross-immunity and vaccines on the survival of less fit flu-strains Miriam Nuño Harvard School of Public Health Gerardo Chowell Los Alamos.
1 The epidemic in a closed population Department of Mathematical Sciences The University of Liverpool U.K. Roger G. Bowers.
Sample Size Determination
Introduction to Regression Analysis, Chapter 13,
Review for Final Exam Some important themes from Chapters 9-11 Final exam covers these chapters, but implicitly tests the entire course, because we use.
Chapter 5: Descriptive Research Describe patterns of behavior, thoughts, and emotions among a group of individuals. Provide information about characteristics.
How does mass immunisation affect disease incidence? Niels G Becker (with help from Peter Caley ) National Centre for Epidemiology and Population Health.
Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media
Infectious Disease Epidemiology Sharyn Orton, Ph.D. American Red Cross, Rockville, MD Suggested reading: Modern Infectious Disease Epidemiology (1994)
Methods to Study and Control Diseases in Wild Populations Steve Bellan, MPH Department of Environmental Sci, Pol & Mgmt University of California at Berkeley.
Regression and Correlation Methods Judy Zhong Ph.D.
Statistical Methods For Engineers ChE 477 (UO Lab) Larry Baxter & Stan Harding Brigham Young University.
Inference for regression - Simple linear regression
Modelling the role of household versus community transmission of TB in Zimbabwe Georgie Hughes Supervisor: Dr Christine Currie (University of Southampton)
Lecture 3: Measuring the Occurrence of Disease
Simulacra & Simulation (& Health Care-Associated Infections) Michael Rubin, MD, PhD Section Chief, Epidemiology VA Salt Lake City Health Care System.
Epidemiology.
Health and Disease in Populations 2001 Sources of variation (2) Jane Hutton (Paul Burton)
Lecture 12 Statistical Inference (Estimation) Point and Interval estimation By Aziza Munir.
Lecture 8: Generalized Linear Models for Longitudinal Data.
University of Ottawa - Bio 4118 – Applied Biostatistics © Antoine Morin and Scott Findlay 08/10/ :23 PM 1 Some basic statistical concepts, statistics.
Basic Probability (Chapter 2, W.J.Decoursey, 2003) Objectives: -Define probability and its relationship to relative frequency of an event. -Learn the basic.
Educational Research: Competencies for Analysis and Application, 9 th edition. Gay, Mills, & Airasian © 2009 Pearson Education, Inc. All rights reserved.
Sample-Based Epidemiology Concepts Infant Mortality in the USA (1991) Infant Mortality in the USA (1991) UnmarriedMarriedTotal Deaths16,71218,78435,496.
Epidemiology With Respect to the Dynamics of Infectious Diseases Huaizhi Chen.
BASICS OF EPIDEMIC MODELLING Kari Auranen Department of Vaccines National Public Health Institute (KTL), Finland Division of Biometry, Dpt. of Mathematics.
Created byInformation Design A Mathematical Model for the Impact of the Conjugate Vaccine on S. pneumoniae Vaccine and Non-vaccine serotypes Robertino.
Various topics Petter Mostad Overview Epidemiology Study types / data types Econometrics Time series data More about sampling –Estimation.
New vaccines mean new strategies: A theoretical exploration of the impact of HPV/HSV vaccines. Geoff Garnett Department of Infectious Disease Epidemiology,
This presentation is made available through a Creative Commons Attribution- Noncommercial license. Details of the license and permitted uses are available.
Multiple Regression and Model Building Chapter 15 Copyright © 2014 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.
Statistical Methods II&III: Confidence Intervals ChE 477 (UO Lab) Lecture 5 Larry Baxter, William Hecker, & Ron Terry Brigham Young University.
Statistical Hypotheses & Hypothesis Testing. Statistical Hypotheses There are two types of statistical hypotheses. Null Hypothesis The null hypothesis,
A Stochastic Model of Paratuberculosis Infection In Scottish Dairy Cattle I.J.McKendrick 1, J.C.Wood 1, M.R.Hutchings 2, A.Greig 2 1. Biomathematics &
Statistical Methods II: Confidence Intervals ChE 477 (UO Lab) Lecture 4 Larry Baxter, William Hecker, & Ron Terry Brigham Young University.
Effect of antiviral use on the emergence of resistance to nucleoside analogs in Herpes Simplex Virus, Type 1 Marc Lipsitch, Bruce Levin, Rustom Antia,
Modeling frameworks Today, compare:Deterministic Compartmental Models (DCM) Stochastic Pairwise Models (SPM) for (I, SI, SIR, SIS) Rest of the week: Focus.
1 Risk Assessment Tests Marina Kondratovich, Ph.D. OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel for Direct-to-Consumer (DTC) Genetic.
Relative Values. Statistical Terms n Mean:  the average of the data  sensitive to outlying data n Median:  the middle of the data  not sensitive to.
Copyright © Cengage Learning. All rights reserved. 13 Linear Correlation and Regression Analysis.
Data and Models for Inferring Expected Effects of PrEP Programs Jim Koopman; Erik Volz; Ethan Romero- Severson; Ed Ionides, Shah Jamal Alam University.
Responding To An Infection Transmission Emergency Jim Koopman MD MPH University of Michigan Center for the Study of Complex Systems & Dept. of Epidemiology.
URBDP 591 I Lecture 4: Research Question Objectives How do we define a research question? What is a testable hypothesis? How do we test an hypothesis?
Introduction to decision analysis modeling Alice Zwerling, Postdoctoral fellow, JHSPH McGill TB Research Methods Course July 7, 2015.
Hypothesis Testing. Suppose we believe the average systolic blood pressure of healthy adults is normally distributed with mean μ = 120 and variance σ.
Chapter 22 Inferential Data Analysis: Part 2 PowerPoint presentation developed by: Jennifer L. Bellamy & Sarah E. Bledsoe.
BUS 308 Entire Course (Ash Course) FOR MORE CLASSES VISIT BUS 308 Week 1 Assignment Problems 1.2, 1.17, 3.3 & 3.22 BUS 308 Week 1.
Stats Methods at IC Lecture 3: Regression.
Incorporating co-morbidity: understanding inequality to improve the value of targeted public health strategies Authors: David Jeffries & Warren Stevens.
Types of risk Market risk
How many study subjects are required ? (Estimation of Sample size) By Dr.Shaik Shaffi Ahamed Associate Professor Dept. of Family & Community Medicine.
Relative Values.
Types of risk Market risk
Stats Club Marnie Brennan
Anatomy of an Epidemic.
Presentation transcript:

Respiratory Bacteria Vaccines: Model Analyses for Vaccine and Vaccine Trial Design Jim Koopman MD MPH Ximin Lin MD MPH Tom Riggs MD MPH Dept. of Epidemiology & Center for Study of Complex Systems University of Michigan

Questions Addressed What role does immunity affecting pathogenicity vs. transmission play in the sharp drop with age in NTHi otitis media? What vaccine effects should be sought and measured in trials? How should vaccine trials be designed to insure adequate power to detect important effects?

General Issues Regarding NTHi Causes 20-40% of acute otitis media Vaccine market 1 billion $ per year in U.S. Infection, immunity, and disease data is meager, non-specific, & highly variable Knowledge of natural history of infection and immunity is deficient Unquestioned assumption that vaccine trials will be individual based and assess disease outcomes

Aspects of NTHi (& many other bacterial) infections Partial immunity, rarely sterilizing –IgA proteases show evolutionary importance of immunity Many variants arise due to transformation competency –No permanent strains yet identified Immunity to colonization or infection, disease, & transmission can be distinct

Using NTHi Models for Inference Models with diverse natural Hx of infection and immunity, age groupings, and contact patterns were constructed Deterministic compartmental (DC) models built first Gradual acquisition of immunity with each colonization and continuous loss over time All models were fit to the full range of data conformations deemed plausible using least squares Projections of vaccine effects made for all fits of all models (about 1000 total) Individual event history stochastic models corresponding to the DC models were used for vaccine trial design

Natural history of NTHi colonization

FA model

Modeling partial immunity Model agent variation and host response as single process Assumptions equal immunity from each colonization multiplicative effects of sequential infections immunity limit (m levels) immunity waning

Modeling partial immunity: S 1 I 1 S 2 I 2 S 3 I 3 ……S m-1 I m-1 S m I m vs. SIR/SIRS/SIS

Aspects of Immunity Modeled Susceptibility Contagiousness Pathogenicity Duration

Preschool children (0.5-5 years) 1.Day-care + Non-day-care 2.9 age groups with 6-month interval School children (5-15 years) Adults Population structure

Contact structure

Death rate of individuals less than 1 year Death rate of individuals aged 1-2 years Death rate of individuals aged 3-4 years Death rate of individuals aged 5-15 years Death rate of individuals aged 15 years and over Annual birth rate into 7-12 month age group Rate at which children enter daycare Rate at which children leave daycare Day-care attendance at 6 months * The units of all rates are year -1. Population parameters

Limited & Highly Variable Epidemiologic data NTHi prevalence by age & daycare attendance (diverse methods) AOM incidence < age 5 by daycare (combine incidence studies & fraction with NTHi studies) Antibody levels by age (diverse methods) Colonization duration (quite limited) Daycare risk ratios for AOM

Low Values High Values Colonization prevalence values fitted Colonization prevalence ages 0-5 when in daycare 23%51% Colonization prevalence ages 0-5 when not in daycare 9.5%21% Colonization prevalence ages 6-157%15% Colonization prevalence in adults4%9% AOM Incidence values fitted Annual NTHi AOM incidence age* < Annual NTHi AOM incidence age Annual NTHi AOM incidence age Annual NTHi AOM incidence age Annual NTHi AOM incidence age

Other Data Antibody levels peak during elementary school Daycare Risk Ratios from 2 to 3 Colonization mean of 2 months but many transient episodes and some long (limited data) Waning “seems” to be relatively fast

Presumptions Before Our Work Very different from Hi Type B Colonization is so frequent, even at older ages, that immunity to transmission cannot be important Trials should assess effects on AOM, not colonization

General assumptions of our model Every colonized individual is infectious Acute otitis media (AOM) is the only relevant disease (Unlike Hi Type B or Strep pneumo) Maternal immunity (Children aged 0-6 months totally immune from colonization)

Fitting model to epidemiologic data Berkeley Madonna: “boundary value ODE…” & optimize functions Empirical identifiability checking Extensive robustness assessment for both data conformation and model conformation rather than estimating variance of estimates

Fitting Results Most efficient level # is 4 Needed immunity profile includes –Susceptibility –Contagiousness –Pathogenicity Contagiousness and Duration Effects are highly co-linear when fitting equilibrium

Parameter values that fit NTHi prevalence & AOM incidence for models without all immunity effects. Immune Effects In The Model (Path effects in all models) Susc S & Infect S & DuratD & I Goodness of Fit (Root Mean Square Error) Duration of immunity (years)  Relative susceptibility after each colonization  Relative contagiousness when re-infected  Relative duration of colonization when re-infected 

Colonization prevalence and AOM incidence data fit* H col H AOM H col L AOM L col H AOM L col L AOM Goodness of fit (root mean square error) Duration of each level of immunity (years), Duration / stage colonization | lowest immunity P(AOM | colonization at the lowest immunity) % decrease in AOM probability per immunity level (pathogenicity effect), % decrease in susceptibility per immunity level, % decrease in contagiousness / immunity level, Effective contact rate per year at general site, Effective contact rate per year at daycare site, Effective contact rate per year at school site,

Data Conformation Fitted AOM Incidence Decrease Colon- ization Prev- alence AOM Inci- dence Immunity Type Decreased 0-1 year 1-2 years 2-3 years 3-4 years 4-5 years High Pathogenicity1.6%3.9%7.9%10.9%12.5% Transmission12.0%9.5%11.8%17.8%23.4% HighLow Pathogenicity1.6%3.8%7.6%10.2%13.2% Transmission23.4%14.6%15.3%23.6%32.8% LowHigh Pathogenicity1.4%2.9%5.1%6.8%8.1% Transmission15.9%19.2%32.6%48.7%62.7% Low Pathogenicity1.8%3.7%6.7%9.0%10.4% Transmission59.7%34.1%33.5%53.2%70.3% Sensitivity Analysis to 10% Change In Pathogenicity or Transmission Immunity

Base analysis from previous Table Only susceptibility effects on transmission Susceptibility and duration effects on transmission Susceptibility, contagiousness, & duration effects on transmission Eight levels of immunity Alternate ratios of contact rates by age at the general mixing site Prevalence and incidence fall more steeply with age Prevalence and incidence fall less steeply with age Simpler pattern of compartments for the natural history of infection and immunity Further Sensitivity Analysis Age 0-1 Age 1-2 Age 2-3 Age 3-4 Age 4-5

Immunity acquisition & waning for P vaccine (Vaccine effects don’t exceed natural immunity effects) Vaccination

Immunity acquiring & waning in vaccinated population: SIP vaccine Vaccination

Vaccination strategy All children at age of 6 months vaccinated

% reduction in AOM incidence among all preschool children as the result of vaccination at birth

% reduction in AOM incidence among preschool children due to vaccination at birth.

Absolute reduction of AOM incidence by age and daycare attendance among preschool children due to vaccination at birth.

AOM cases among daycare and non-daycare children from a population of 1,000,000 before and after vaccination at birth with SIP vaccines.

Summary of Deterministic Model Findings Wide range of feasible models fit to a wide range of feasible data Over this entire huge range, the intuition that immune effects on pathogenicity are the major determinants of AOM incidence proves to be wrong Trials must assess transmission

Model Refinements Desirable Model agent strains with different degrees of cross reacting immunity Incorporate evolution of agent into vaccine effect assessment Make maternal immunity and acquisition time for vaccine immunity more realistic

Additional Practical Need for Indirect Effects Very young age of highest risk means little time to get all the booster effects needed

Using NTHi Models for Inference About Vaccine Trial Design Convert deterministic compartmental model to individual event history model Add distinct daycare units and families Construct vaccine trials assessing colonization in the IEH models with varying randomization schemes, vaccine effects exceeding natural immunity, sample collection periods, serology & typing results Hundreds of thousands of vaccine trial simulations performed

Conclusions from Vaccine Trial Simulations Most efficient randomization unit is daycare –Individual randomized trials run too much risk of missing important vaccine effects Standard power calculation methods for Group Randomized Trials are far off because they are based on individual effect Role of inside vs. outside transmission in daycare significantly affects power Molecular assessment of transmission worthwhile

Standard variance calculation in Group Randomized Trials (GRTs) variance: ICC: intraclass correlation Assumes objective is measurement of individual effects

ICC & Vaccine effect

Change in Variance with Daycare Size & Sample Size

Preliminary results (1): variance & immunity

Simple Model For Insight S S* I Equilibrium distribution of states solved theoretically for daycare with 12 children Vaccine effect decreases susceptibility by 50%

Unvacc mostly within trans 30%Prev Vacc mostly within trans Unvacc mostly outside trans Vacc mostly outside trans

Unvacc mostly within trans 50%Prev Vacc mostly within trans Unvacc mostly outside trans Vacc mostly outside trans

Significance of S & S* Contribution to Power Calculation Serological ability to assess cumulative infection level would contribute considerably to power

Empirical power calculation

Empirical power & the number of the pairs of daycare centers

Why standard power calculations for GRTs are way off ICC is determined by transmission dynamics Effect is determined by transmission dynamics Power is not just determined a single outcome state but by correlated infection and immunity states

Thank You